---
title: 'Senior Director, Sponsor Oversight and Monitoring Effectiveness at Dyne Therapeutics'
canonical: 'https://feeny.ai/job/senior-director-sponsor-oversight-and-monitoring-effectiveness-dyne-xgtf2wewr294'
type: 'job'
last_seen: '2026-11-02'
---

# Senior Director, Sponsor Oversight and Monitoring Effectiveness at Dyne Therapeutics

- **Company:** Dyne Therapeutics
- **Location:** Waltham, MA
- **Compensation:** $260k–$295k
- **Posted:** 2026-10-28
- **Last confirmed live:** 2026-11-02
- **Apply:** https://job-boards.greenhouse.io/dynetherapeutics/jobs/6236379004

## Job description

Company Overview:

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at [https://www.dyne-tx.com/](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DaBhdU0rLyxqDF5MLc_hIfw7usSG4P5AlGZUt689alyH6v7mzOmFdpd9s5X8DlnvZSiEkR5UEisX91xRDuQTa2VgG02ByJmFzR8fXOPz8Zi8%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825271389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=J6tnBKJnocuFhoQSNnLD03mlmX8CCP4Ufz89Tz2BRqY%3D&reserved=0), and follow us on [X](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DLBKooGRVe4UrE2Sa6ReueOswzx2nXn5X8MuiTcNNQ_6lX0cFP8Xf24jpFASx3QmF9Qt-1g3RGsigqX34LIiwMg%3D%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825316922%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=1SaJTlzgJLAz3INco8zVJpHByglVu9H3uR4eaUUwqbY%3D&reserved=0), [LinkedIn](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DV9e03kLdDWSbh0_VwnuvS9iTb21RRXsSKiAaMEbducMXKsrR2S-Gw7FLuap5gHCzvcaUIvGPyAeg1wRzFGrqW9J_Z6Ha8bGtJaWV9voKp-c%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825339609%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bDmOn9uD5vB9%2F2LttEyLg%2BANoH6v3vDFv7SAwVdi%2BoI%3D&reserved=0) and [Facebook](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DCMyzCcuOkxGNqTNEki-upZwJJPBCJLp0a-MvjKwwfPo1XQp8XutL02Vy2Vg3ZmpnCYnPLhHxcgEzFeh-07gg_rWzXbiw64-AClVkXbKyKQs%3D&data=05%7C02%7Cjinna.oh%40dyne-tx.com%7C0a9e83cf0dad4bb9d7f808defa05885d%7Cebfdf398d6a6477eace4f79a019fa3aa%7C0%7C0%7C639223098825359448%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=exQuTFG7FGBX1V0XPy4zSebLvhQUDksB19Nej8Eg3DQ%3D&reserved=0).

Role Summary:

The Senior Director, Sponsor Oversight and Monitoring Effectiveness (SOME) is the founding leader of this function within Clinical Operations. This leader sets oversight strategy, designs risk-based monitoring approaches, and provides oversight capacity, including its forecasting. The role safeguards investigator site quality and confirms key vendor activities, and CRO monitoring meets the highest standards of quality, compliance, and patient focus. This leader develops the operating model, standards, governance, analytics, and targeted oversight activities used to evaluate CRO monitoring, investigator-site quality, and emerging clinical trial risks across Dyne’s portfolio.

Working in close partnership with Clinical Operations Program and Study Leads, Clinical Business Operations, Quality Assurance, Data Management, Biostatistics, Medical, CRO partners and key vendors, this role translates risk signals into timely recommendations, interventions, and escalations that protect participants and support reliable clinical data. The role provides assurance and functional expertise while preserving Study Management’s accountability for trial execution and Quality Assurance’s independent compliance responsibilities.

This role is based in Waltham, MA.

Primary Responsibilities Include:

Build the capability and own oversight strategy

- Design and establish Dyne’s sponsor oversight and monitoring effectiveness operating model, including governance, Standard Operating Procedures (SOPs), templates, training, and capacity planning aligned with ICH GCP.
- Create and implement Study-Specific Oversight Plans (SSOPs) aligned with each study’s risk management and monitoring plans, covering CRO monitoring and key vendors.
- Establish standards for assurance, escalation, and targeted intervention while maintaining clear accountability within Clinical Operations and partnership with Quality Assurance (QA).
- Serve as Clinical Operations’ accountable owner for sponsor oversight of CRO monitoring and key vendor performance during audits and regulatory inspections.

Design and drive monitoring strategy

- Set Dyne’s monitoring standards using quality by design and Risk-Based Quality Management (RBQM), including critical-to-quality factors, Key Risk Indicators (KRIs), Quality Tolerance Limits (QTLs), and centralized monitoring.
- Shape CRO monitoring plans during protocol development and study start-up to protect patient safety and data integrity.
- Analyze site and study risk, identify emerging issues, and drive timely intervention and corrective action.
- Establish and track monitoring-effectiveness metrics, including visit report timeliness, action-item closure, protocol deviation detection, and Trial Master File (TMF) and Investigator Site File (ISF) completeness.
- Evaluate whether monitoring activities identify material risks in a timely manner, result in appropriate corrective action, and improve patient safety, protocol compliance, and data reliability.
- Shape the monitoring model as Dyne transitions to a hybrid outsourcing model.

Provide functional leadership across Sponsor Oversight & Monitoring Effectiveness

- Safeguard quality at investigator sites through risk-based surveillance, aggregate data review, and targeted Sponsor Oversight Visits (SOVs).
- Develop a portfolio-level view of site, study, CRO monitoring, and key vendor risk; identify cross-study trends and systemic issues; and recommend enterprise-level interventions and process improvements.
- Communicate oversight findings to study teams, CROs, key vendors, and Clinical Operations leadership, escalating significant quality issues through established governance.
- Define and monitor CRO and Functional Service Provider (FSP) expectations for CRA qualifications, training, workload, continuity, visit execution, report quality, issue escalation, and corrective-action effectiveness.
- Define and monitor key vendor expectations for qualified personnel, training, system validation, data quality, turnaround times, issue escalation, and corrective-action effectiveness.
- Serve as the Clinical Operations subject-matter expert for sponsor oversight and monitoring during audits and regulatory inspections, ensuring oversight activities, decisions, escalations, and evidence are complete, traceable, and inspection-ready.

Collaborate across functions and governance

- Partner with Clinical Operations Program Leads (COPLs), study teams, Clinical Business Operations, QA, Medical, Data Management, Biostatistics, Clinical Systems, and Portfolio Analytics & Systems to integrate operational, clinical, and quality data into actionable risk signals.
- Translate risk signals into fit-for-purpose monitoring and oversight interventions in partnership with study teams, CROs, and key vendors.
- Report portfolio oversight status, trends, risks, and recommendations to leadership and CRO and key vendor governance forums.
- Model Dyne’s values and leadership expectations by fostering trust, collaboration, inclusion, accountability, and high performance.

Education and Skills Requirements:

- Bachelor’s degree in a life science, nursing, or related field required. Advanced degree (Master’s, PharmD, or PhD) or RN licensure preferred
- 12+ years of progressive responsibility in clinical operations at a biotech, pharma, or CRO, including at least 5 years leading people managers or functional teams
- Hands-on monitoring experience as a Clinical Research Associate (CRA) or monitoring manager, plus direct experience overseeing CRO monitoring
- Proven delivery of RBQM, centralized monitoring, or quality-by-design programs
- Deep working knowledge of ICH E6(R3), ICH E8(R1) General Considerations for Clinical Studies, and Food and Drug Administration (FDA) and European Medicines Agency (EMA) expectations for sponsor oversight of CROs and other service providers
- Experience managing a CRO, or other key vendors: scope, metrics, invoices, and forecasting.
- Direct experience overseeing key clinical trial vendors beyond the CRO, such as central laboratories, imaging, physical therapy, and other providers.
- Direct experience hosting or supporting regulatory inspections
- Executive presence, with a record of turning risk signals into clear recommendations for senior leaders
- Demonstrated experience building capabilities and leading direct reports, subject-matter experts, consultants, or matrixed teams
- Experience establishing a new sponsor oversight, RBQM, or centralized monitoring capability
- Experience with global Phase 2/3 or registration-enabling studies
- Rare disease, pediatric, neuromuscular, or genetic-medicine experience
- Experience operating in a hybrid outsourcing model
- Experience with RBQM platforms, clinical analytics, CTMS, EDC, and eTMF data
- Experience evaluating CRA capacity, quality, and monitoring-model effectiveness
- Experience with FDA BIMO or comparable global GCP inspections
- Experience supporting major regulatory submissions
- Ability to travel (generally less than 50%, including local, regional, and international)

#LI-Onsite MA Pay Range $260,000—$295,000 USD

The pay range reflects the base pay range Dyne reasonably expects to pay for this role at the time of posting. Individual compensation depends on factors such as education, experience, job-related knowledge, and demonstrated skills.

The statements contained herein reflect general details as necessary to describe the principles functions for this job, the level of knowledge and skill typically required, and the scope of responsibility, but should not be considered an all-inclusive listing of work requirements.  Individuals may perform other duties as assigned, including work in other functional areas to cover absences or relief, to equalize peak work periods or otherwise balance workload.

Dyne Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.

## About Dyne Therapeutics

## Company Overview
- **One-liner**: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted nucleic acid therapies for genetically driven neuromuscular diseases using its proprietary FORCE™ platform.
- **Entity Type**: Public (NASDAQ: DYN)
- **Headquarters**: Waltham, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Not publicly available (the company was co-founded by a team of scientists and entrepreneurs; individual names not surfaced in search results)

## Core Business
- **Primary industry**: Biotechnology / Biopharmaceuticals – rare neuromuscular disease therapeutics
- **Target customers**: B2B / B2G – regulatory agencies, healthcare providers, payers, and most importantly patients with Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease.
- **Mission / Purpose**: “Delivering functional improvement for people living with neuromuscular diseases.” [dyne-tx.com](https://www.dyne-tx.com/)

## Products & Services
Dyne’s pipeline is built around its FORCE™ platform, which uses an antigen-binding fragment (Fab) conjugated to transferrin receptor 1 (TfR1) to deliver therapeutic payloads to muscle and the central nervous system.

- **Z‑rostudirsen (DYNE‑251)** – An investigational therapeutic for DMD patients amenable to exon 51 skipping. Consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to an anti‑TfR1 Fab. Phase 1/2 DELIVER trial met primary endpoint; BLA submission for U.S. Accelerated Approval planned for Q2 2026 with potential launch in Q1 2027. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
- **Z‑basivarsen (DYNE‑101)** – Investigational therapeutic for DM1, using an antisense oligonucleotide (ASO) conjugated to anti‑TfR1 Fab. Phase 1/2 ACHIEVE trial fully enrolled; Phase 3 HARMONIA trial ongoing. [dyne-tx.com](https://www.dyne-tx.com/pipeline/)
- **DYNE‑302** – Preclinical candidate for FSHD, using an siRNA payload to suppress DUX4 expression. [dyne-tx.com](https://www.dyne-tx.com/pipeline/)
- **DMD Franchise Expansion** – Four additional development candidates (DYNE‑253, DYNE‑245, DYNE‑244, DYNE‑255) targeting exons 53, 45, 44, and 55 for DMD, entering IND‑enabling studies. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)

## Market Standing
- **Valuation / Market Cap**: Not disclosed in search results (public company; market cap fluctuates with stock price; current figure not provided in the sources).
- **Key Metric**: Cash, cash equivalents and marketable securities of **$1.1 billion** as of December 31, 2025, providing runway into Q1 2028. [investors.dyne-tx.com](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
- **Notable Investors / Partners**: Not listed in provided search results (likely institutional investors; prior venture rounds not detailed here).
- **Growth Signals**:
  - Headcount grew **38.2% YoY** to **227 employees** (2025). [linkedin.com](https://www.linkedin.com/company/dynetx)
  - Positive topline results from DELIVER trial for z‑rostudirsen; potential first product launch in Q1 2027 if approved.
  - Advancing five distinct clinical/preclinical programs across multiple neuromuscular indications.

## Competitive Advantages
- **FORCE™ Platform**: Differentiated delivery technology that uses a TfR1‑binding Fab to enable broad and deep tissue penetration in both muscle and CNS – addressing one of the biggest hurdles in neuromuscular drug development.
- **Best‑in‑Class Potential**: Clinical data for z‑rostudirsen showed statistically significant dystrophin expression (5.46% of normal at 6 months, 7‑fold change) and preservation of lung function (FVC%p) compared to placebo, despite a small trial not powered for functional endpoints.
- **Broad Pipeline**: Covering multiple exon‑skipping opportunities in DMD as well as entirely different diseases (DM1, FSHD, Pompe) with the same core platform, reducing risk and enabling rapid expansion.

## Strategic Focus
- **Regulatory Submission**: File a Biologics License Application (BLA) for z‑rostudirsen in Q2 2026 under U.S. Accelerated Approval pathway.
- **Late‑Stage Trials**: Initiate two field‑defining Phase 3 confirmatory trials (FORZETTO for DMD and HARMONIA for DM1) in 2026 following FDA alignment on design.
- **Pipeline Expansion**: Move four additional DMD exon‑skipping candidates into IND‑enabling studies and advance preclinical DYNE‑302 (FSHD) toward the clinic.
- **Commercial Readiness**: Prepare for potential first‑ever company launch in Q1 2027 with a focus on U.S. market, while also pursuing ex‑U.S. approval pathways.

## Why Work Here
- **Mission‑Driven Culture**: The company’s “One Dyne community” ethos emphasizes accountability, transparency, fearlessness, and a relentless drive to deliver functional improvement for patients and families. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/)
- **Competitive Benefits**: Medical, dental, vision, 401(k), flexible vacation, paid holidays including a year‑end office closure, short‑ & long‑term disability, HSA/FSA accounts. [dyne-tx.com](https://www.dyne-tx.com/careers-culture/)
- **Work Environment**: Office location in Waltham, MA (Boston area). Remote/hybrid policy not specified in search results; likely on‑site or hybrid for lab‑based roles. Career page lists roles such as Associate Director, Oligonucleotide Development; Scientist, RNA; Director of Training – reflecting a mix of research, clinical, and corporate functions. [job-boards.greenhouse.io](https://job-boards.greenhouse.io/dynetherapeutics)
- **Growth Opportunity**: Joining a late‑stage biotech with a validated platform, strong cash position, and a clear path to commercialization – offering employees exposure to both R&D and upcoming launch activities.
- **Recruitment Scam Warning**: Dyne posts an explicit notice on its careers page that it never requests financial details or payment during hiring; all legitimate emails come from @dyne‑tx.com addresses.

## Sources
1. [dyne-tx.com – Company Overview](https://www.dyne-tx.com/)
2. [dyne-tx.com – Careers & Culture](https://www.dyne-tx.com/careers-culture/)
3. [dyne-tx.com – Pipeline](https://www.dyne-tx.com/pipeline/)
4. [investors.dyne-tx.com – Q4/Full Year 2025 Results](https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-fourth-quarter-and-full-year-2025)
5. [linkedin.com – Dyne Therapeutics Company Profile](https://www.linkedin.com/company/dynetx)
6. [job-boards.greenhouse.io – Dyne Careers Page](https://job-boards.greenhouse.io/dynetherapeutics)

## Other roles at Dyne Therapeutics

- [Senior Research Associate, Histology & Microscopy](https://feeny.ai/job/senior-research-associate-histology-microscopy-dyne-therapeutics-waltham-z7ypgr0zc049) — Waltham, MA
- [Director, Oligonucleotide Manufacturing](https://feeny.ai/job/director-oligonucleotide-manufacturing-dyne-therapeutics-waltham-0bgz63bxkahb) — Waltham, MA
- [Associate Director, Analytical Development](https://feeny.ai/job/associate-director-analytical-development-dyne-therapeutics-waltham-k8tnm780t8yk) — Waltham, MA
- [Director, Government Pricing & Contract Operations](https://feeny.ai/job/director-government-pricing-contract-operations-dyne-therapeutics-waltham-jk69cejw4737) — Waltham, MA
- [Senior Director, Medical Affairs Biostatistics](https://feeny.ai/job/senior-director-medical-affairs-biostatistics-dyne-therapeutics-waltham-2f5wq33kjtjp) — Waltham, MA
- [Director, Cost Accounting](https://feeny.ai/job/director-cost-accounting-dyne-therapeutics-waltham-k8qpf11tf80c) — Waltham, MA
- [Director, Revenue](https://feeny.ai/job/director-revenue-dyne-therapeutics-waltham-t62v02kw61st) — Waltham, MA
- [Associate Director, Market Research & Competitive Intelligence](https://feeny.ai/job/associate-director-market-research-competitive-intelligence-dyne-therapeutics-qc47ze0xw76k) — Waltham, MA
- [Associate Director, Medical Information and Review](https://feeny.ai/job/associate-director-medical-information-and-review-dyne-therapeutics-waltham-ff9hs10jh3sd) — Waltham, MA
- [Senior Administrative Assistant - US Affiliate](https://feeny.ai/job/senior-administrative-assistant-us-affiliate-dyne-therapeutics-waltham-y3emed522zqq) — Waltham, MA